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Home-Based Walking Exercise in Peripheral Artery Disease:
12-Month Follow-up of the Goals Randomized Trial
Mary M. McDermott, MD; Jack M. Guralnik, MD, PhD; Michael H. Criqui, MD, MPH; Luigi Ferrucci, MD, PhD; Lihui Zhao, PhD;
Kiang Liu, PhD; Kathryn Domanchuk, BS; Bonnie Spring, PhD; Lu Tian, ScD; Melina Kibbe, MD; Yihua Liao, MS; Donald Lloyd Jones, MD, ScM;
W. Jack Rejeski, PhD
Background-—We studied whether a 6-month group-mediated cognitive behavioral (GMCB) intervention for peripheral artery
disease (PAD) participants, which promoted home-based walking exercise, improved 6-minute walk and other outcomes at 12-
month follow-up, 6 months after completing the intervention, compared to a control group.
Methods and Results-—We randomized PAD participants to a GMCB intervention or a control group. During phase I (months 1 to
6), the intervention used group support and self-regulatory skills during weekly on-site meetings to help participants adhere to
home-based exercise. The control group received weekly on-site lectures on topics unrelated to exercise. Primary outcomes were
measured at the end of phase I. During phase II (months 7 to 12), each group received telephone contact. Compared to controls,
participants randomized to the intervention increased their 6-minute walk distance from baseline to 12-month follow-up, (from
355.4 to 381.9 m in the intervention versus 353.1 to 345.6 m in the control group; mean difference=+34.1 m; 95% confidence
interval [CI]=+14.6, +53.5; P<0.001) and their Walking Impairment Questionnaire (WIQ) speed score (from 36.1 to 46.5 in the
intervention group versus 34.9 to 36.5 in the control group; mean difference =+8.8; 95% CI=+1.6, +16.1; P=0.018). Change in the
WIQ distance score was not different between the 2 groups at 12-month follow-up (P=0.139).
Conclusions-—A weekly on-site GMCB intervention that promoted home-based walking exercise intervention for people with PAD
demonstrated continued benefit at 12-month follow-up, 6 months after the GMCB intervention was completed.
Clinical Trial Registration-—URL: ClinicalTrials.gov. Unique identifier: NCT00693940. ( J Am Heart Assoc. 2014;3:e000711 doi:
10.1161/JAHA.113.000711)
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S upervised treadmill exercise significantly improves walk-ing performance in people with lower-extremity periph-
eral artery disease (PAD).1–4 However, 3 times weekly travel
to the medical center for supervised exercise is burdensome
for people with PAD and medical insurance does not cover
supervised treadmill exercise. Thus, most people with PAD do
not participate in supervised treadmill exercise programs.5 In
addition, whether benefits from supervised treadmill exercise
are sustained after PAD patients complete a supervised
exercise program is unclear. Identifying a walking exercise
program that does not require 3 times weekly travel to the
medical center and achieves sustained improvement in
walking performance over long-term follow-up is an important
treatment goal for people with PAD.
In the Group Oriented Arterial Leg Study (GOALS), we
recently reported that a 6-month group-mediated cognitive
behavioral (GMCB) intervention, consisting of weekly visits to
an exercise facility that incorporated group support and self-
regulatory skills, helped PAD participants adhere to home-
based walking exercise activity and significantly improved their
6-minute walk, treadmill walking performance, physical activity
levels, and patient-perceived walking performance.6 By
encouraging PAD patients to integrate walking exercise into
their daily routine, the GOALS intervention may provide
sustained benefit over long-term follow-up, by promoting
adherence to home-based walking exercise even after the
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weekly on-site intervention meetings are completed. We
previously reported 6-month follow-up data for the GOALS
trial.6 A secondary aim of the GOALS trial is to determine
whether the GOALS intervention was associated with change in
6-minute walk, physical activity, and patient-reported out-
comes between baseline and 12-month follow-up, compared to
the control group. This report describes results of this
secondary aim in the GOALS trial. We hypothesized that PAD
patients randomized to the intervention would have signifi-
cantly better walking performance at 12-month follow-up,
6 months after the on-site intervention was completed,
compared to PAD participants randomized to the control group.
Methods
GOALS trial methods have been reported.7 The institutional
review board of Northwestern University Feinberg School of
Medicine (Chicago, IL) approved the protocol. Participants
provided written informed consent and were randomized to 1
of 2 groups: a GMCB home-based exercise intervention versus
attention control group. During phase I (months 1 to 6),
participants randomized to the intervention attended weekly
on-site group meetings at an exercise center, during which
group support and self-regulatory skill instruction were
employed to help participants adhere to home-based walking
exercise. During phase I, participants randomized to the
control group attended weekly on-site group meetings at the
medical center, during which they received health educational
lectures on topics not related to exercise (Figure 1). Primary
outcomes were obtained after phase I, at 6-month follow-up,
and results have been reported.6 During phase II (months 7 to
12), participants randomized to the intervention received
telephone calls from their group facilitator (Figure 1). During
phase II, participants randomized to the control group
received telephone calls from a study coordinator with
information related to the educational sessions in phase I.
In this report, we describe results of the secondary aim of
the GOALS trial, to determine whether the 6-month on-site
GMCB intervention was associated with greater improvement
in study outcomes between baseline and 12-month follow-up,
compared to the control group. The study was performed in
Chicago, Illinois, between July 22, 2008 and May 2, 2013.
Participant Recruitment
Recruitment methods have been reported6,7 and are summa-
rized here. Participants were recruited through newspaper or
radio advertisements, from postcards mailed to people age 65
and older in the Chicago area, and from practicing physicians
at Northwestern. People with PAD who had previously
194 eligible participants 
randomized into the GOALS 
Trial
Phase I (Months 1-6):
Group Mediated Cognitive 
Behavioral sessions each week 
at the exercise center 
Phase I (Months 1-6): 
Health education lectures each 
week at the medical center
178 completed six-month follow-up testing.
Phase II (Months 7-12):
Telephone contact only
Intervention (N=97) Control (N=97)
Phase II (Months 7-12):
Telephone contact only
168 completed twelve-month follow-up testing
Intervention (N=88) Control (N=90)
Control (N=87)Intervention (N=81)
9 lost to 
follow-up
7 lost to 
follow-up
N=3 lost to follow-up
N=7 lost to 
follow-up
Figure 1. Study design of the Group Oriented Arterial Leg Study (GOALS) trial.
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participated in research with the investigative team and
expressed interest in future research studies were contacted.
Inclusion and Exclusion Criteria
The inclusion criterion was an ankle brachial index (ABI) ≤0.90
in either leg. Individuals with a resting ABI ≥0.91 and ≤1.00 at
baseline were eligible if their ABI dropped by ≥20% after a
heel-rise test.8 Individuals with a resting ABI >0.90 were
eligible if they provided medical record documentation of
lower-extremity revascularization or evidence of PAD from an
accredited vascular laboratory. Exclusion criteria included:
below- or above-knee amputation, wheelchair confinement,
inability to walk at least 50 feet without stopping, use of a
walking aid other than a cane, inability to attend weekly
sessions, walking impairment for a reason other than PAD,
foot ulcer or critical limb ischemia, and significant visual or
hearing impairment.6,7 Potential participants who did not
complete the study run-in had major surgery or lower-
extremity revascularization during the previous 3 months or
planned during the next 12 months, had major medical
illness, or were participating in another clinical trial or had
been in another exercise trial or cardiac rehabilitation within
the past 3 months were excluded.6,7 Potential participants
with Parkinson’s disease, and those requiring oxygen with
activity or exercise were excluded.6,7 Potential participants for
whom exercise may be unsafe were excluded. Participants
already exercising at a level similar to that targeted in the
intervention were excluded. Potential participants with cog-
nitive impairment at baseline were excluded.9
ABI Measurement
A hand-held Doppler probe (Pocket Dop II; Nicolet Biomedical
Inc., Golden, CO) was used to obtain systolic pressures in the
right and left brachial, dorsalis pedis, and posterior tibial
arteries using established methods.2,7,10,11 Systolic pressures
of zero were excluded from ABI calculations.
Medical History
Medical history, race, and demographics were obtained using
patient report.2,6,7
Leg Symptoms
Leg symptoms were characterized using the San Diego
Claudication Questionnaire.12 Most patients with PAD do not
have classic symptoms of intermittent claudication.13 To
enhance the generalizability of the GOALS trial, we included
eligible PAD participants even if they did not have classic
intermittent claudication symptoms.6,7 Intermittent claudica-
tion (IC) was defined as exertional calf pain that does not
begin at rest, causes the participant to stop walking, and
resolves within 10 minutes of rest.12,13 Participants without
IC were either asymptomatic (ie, reported no exertional leg
symptoms) or had leg symptoms not meeting all criteria
for IC.12,13
Outcomes
All outcomes were measured before randomization and at 12-
month follow-up by assessors unaware of participants’ group
assignment.
Primary Outcome: 6-Minute Walk Test
Following a standardized protocol,2,6,7,14–16 participants
walked up and down a 100-foot hallway for 6 minutes after
instructions to cover as much distance as possible. The
distance completed after 6 minutes was recorded.
Secondary Outcomes
Physical activity
Physical activity was measured over 7 days using a vertical
accelerometer (Caltrac; Muscle Dynamics Fitness Network,
Inc., Torrance, CA) according to established, validated meth-
ods.17–19 Because accelerometers were programmed using
identical age, weight, and sex for each participant, the
measurement yielded “activity units.”17–19 Participants were
also asked about the number of city blocks walked in the past
week (exploratory outcome).19,20 Previous study shows that
the specific questionnaire administered to obtain information
on blocks walked during the past week correlates with
objectively measured physical activity level in people with
PAD (correlation=0.25; P<0.001).20
The Walking Impairment Questionnaire
The Walking Impairment Questionnaire (WIQ) is a PAD-specific
measure of self-reported limitations with 3 domains: walking
distance; walking speed; and stair climbing.21 Each domain is
scored on a 0 to 100 scale, where 0 represents extreme
limitation and 100 represents no difficulty walking long
distances, walking rapidly, or climbing 3 stair flights, respec-
tively.21
Quality of life
The physical (PCS) and mental health (MCS) composite scores
from the Medical Outcomes Study 12-Item Short-Form Health
Survey (SF-12) were used to assess global dimensions of
health-related quality of life.22 These measures were selected
as outcomes because they were generic measures of quality
DOI: 10.1161/JAHA.113.000711 Journal of the American Heart Association 3
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of life and our aim was to determine whether the intervention
influenced this well-validated general measure of quality of
life. The specific quality-of-life domains selected were more
likely to change in response to the intervention than other
Medical Outcomes Study 36-Item Short-Form Health Survey
domains, based on the nature of the intervention.
Other Measures
Height and weight were measured at baseline.7 Body mass
index was calculated as weight (kg)/(height [meters])2.
Randomization
Eligible participants were randomized by computer using
a randomly permuted block method, stratifying by baseline
6-minute walk performance.7
Study Interventions
Phase I of the GMCB intervention (months 1 to 6)
As previously described, the GOALS intervention applied
principles from social cognitive theory, the group dynamics
literature, and research on self-regulation to motivate partic-
ipants to adhere to home-based walking exercise.23–25 During
phase I (months 1 to 6) of the intervention, participants met
once-weekly for 90 minutes in a group with other PAD
participants and a trained facilitator. The facilitator led
discussion on a different topic each week, including goal
setting and self-monitoring.7 Participants were instructed to
engage in over-ground walking exercise at least 5 days per
week at home, working up to 50 minutes per exercise
session. Each week, participants recorded their walking goals
on a study questionnaire. Participants were asked to record
their actual walking exercise activity on this questionnaire
each day. Primary outcomes were measured at 6-month
follow-up, at the completion of phase I (Figure 1).
Phase I of the control group (months 1 to 6)
During phase I, participants assigned to the control group
attended weekly educational group sessions with other PAD
participants. Physicians and other healthcare professionals
provided lectures on topics including managing hypertension,
cancer screening, and vaccinations.
Phase II of the intervention and control groups (months
7 to 12)
During phase II (months 7 to 12), participants received
regularly scheduled telephone calls from their group facilita-
tor. For participants in the intervention, the telephone calls
were designed to re-enforce self-regulation principals empha-
sized in phase I and encourage continued home-based
exercise. As during phase I, participants were encouraged to
walk over ground for exercise. Participants in the intervention
were asked to record their daily walking exercise activity on
the study questionnaire and mail these questionnaires back to
study investigators. For participants in the control group, the
telephone calls reviewed the health education topics covered
during group sessions in phase I. For both groups, telephone
calls in phase II occurred biweekly in months 7 to 9 and once-
monthly in months 10 to 12. Telephone calls in each group
lasted 10 minutes.
Sample-Size Calculations
Our prespecified comparison for 12-month outcomes was the
change between baseline and 12-month follow-up. Power
calculations for change in 6-minute walk between baseline and
12-month follow-up were based on power calculations for our
primary outcome of change in 6-minute walk at 6-month
follow-up and assumed that 100 people completing 6-month
follow-up testing in each group would provide 80% power to
detect a difference of 0.40 SDs of the pooled 6-month change
in 6-minute walk distance between the exercise and control
groups at the significance level of 0.05.7 This difference
corresponded to 21.6 m in the 6-minute walk using the
estimated SD in our previous study of supervised exercise2 and
represents a small meaningful difference in the 6-minute walk
test.26 We expected that the improvements observed in the
intervention group at 6-month follow-up would largely be
maintained at 12 months and that participants in the control
group would experience decline in their 6-minute walk between
6- and 12-month follow-up. Therefore, between-group differ-
ences in changes in functional performance from baseline to
12-month follow-up were expected to remain >0.40 SDs, and a
sample size of 100 participants in each group was expected to
provide sufficient statistical power. Comparisons between 6-
and 12-month follow-up were not prespecified, and power
calculations were not performed for these comparisons.
Statistical Analyses
Chi-square tests and 1-way ANOVAs were used to compare
categorical and continuous characteristics of participants in
the intervention and control groups, respectively, who com-
pleted 12-month follow-up testing. Two-sample, 2-sided t
tests were used to compare changes in outcomes between
baseline and 12-month follow-up between the intervention
and the control group. These analyses were completed in
exploratory analyses comparing changes in outcomes
between 6- and 12-month follow-up. A priori, the P value
considered statistically significant was P<0.05. Intention-to-
treat analyses were performed. Specifically, all participants
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were asked to return for follow-up measurements, regardless
of their adherence to their assigned group. Decedents were
excluded from analyses. We also performed multiple imputa-
tion analyses to adjust for missing data. We performed 2 sets
of multiple imputation analyses: one in which decedents were
excluded and one in which decedents were assigned a score
of zero for follow-up measures. In addition, because partic-
ipants attending the 12-month follow-up visit may no longer
reflect the original randomization, we repeated analyses,
adjusting for characteristics that appeared unbalanced
between the intervention and control groups. In exploratory
analyses, tests for statistical interactions were performed to
determine whether presence versus absence of intermittent
claudication influenced responsiveness to the study interven-
tion. Analyses were performed using SAS statistical software
(version 9.2; SAS Institute Inc., Cary, NC).
Results
We identified 194 eligible participants during the study
recruitment period. Of the 194 participants randomized,
168 (86.6%) completed 12-month follow-up testing. Sixteen
participants in the intervention group (including 3 decedents)
and 10 in the control group (including 2 decedents) did not
complete 12-month follow-up testing. Randomized partici-
pants who did not return for 12-month follow-up testing were
younger (65.010.2 versus 71.09.3 years; P=0.003),
compared to participants who returned for follow-up testing.
Table 1 compares characteristics of participants randomized
to the intervention and control conditions. As compared to the
control group, those in the intervention were slightly younger,
included more African Americans, and had a higher physical
activity level at baseline (Table 1). However, only the differ-
ence in accelerometer-measured physical activity was statis-
tically significant (P=0.048). Among 81 participants
randomized to the intervention, 68 (84%) recorded their
exercise data for at least 1 week during months 7 to 12.
During months 7 to 12, the mean number of minutes walked
for exercise was 207.7118.9 min/week. In comparison,
during months 1 to 6, the mean number of minutes walked for
exercise was 195.098.1 min/week. Figure 2 shows 6-
minute walk performance at each study time point in the
Table 1. Baseline Characteristics of the Intervention and Control Groups Among GOALS Participants Who Completed 12-Month
Follow-up Testing*
Baseline Measures Entire Cohort (N=168) Control (N=87) Intervention (N=81)
Age, y 71.0 (9.3) 72.0 (9.3) 69.9 (9.2)
Male, % 48.8 49.4 48.2
African American, % 48.2 41.4 55.6
Ankle brachial index 0.68 (0.17) 0.68 (0.18) 0.67 (0.16)
Body mass index, kg/m2 28.9 (6.6) 29.0 (6.7) 28.7 (6.5)
Current smoker, % 21.4 18.4 24.7
Angina, % 15.0 15.1 14.8
History of myocardial infarction, % 13.7 13.8 13.6
History of heart failure, % 12.0 12.6 11.1
Stroke, % 13.1 17.2 8.6
Pulmonary disease, % 12.5 12.6 12.4
Cancer, % 16.2 17.4 14.8
Diabetes mellitus, % 33.9 36.8 30.9
Intermittent claudication symptoms, % 26.8 24.1 29.6
PAD participants without classic symptoms of intermittent claudication, % 73.2 75.9 70.4
Six-minute walk, m 354.2 (95.0) 353.1 (92.6) 355.4 (98.1)
WIQ distance score (0 to 100 scale, 100=best) 33.8 (26.7) 33.2 (26.3) 34.4 (27.2)
WIQ speed score (0 to 100 scale, 100=best) 35.5 (23.5) 34.9 (23.1) 36.1 (24.0)
WIQ stair climbing score (0 to 100 scale, 100=best) 48.2 (25.6) 46.8 (25.2) 49.7 (26.1)
Physical activity (activity units) 726.4 (374.0) 671.3 (335.4) 785.6 (404.3)
GOALS indicates Group Oriented Arterial Leg Study; PAD, peripheral artery disease; WIQ, Walking Impairment Questionnaire.
*Data shown are percentage values or means (standard deviations).
DOI: 10.1161/JAHA.113.000711 Journal of the American Heart Association 5
Home-Based Exercise Trial in PAD McDermott et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
intervention and control groups. Six-minute walk performance
was significantly better in the intervention, as compared to
the control, group at both 6- and 12-month follow-up. At 12-
month follow-up, participants in the intervention had signif-
icantly greater improvement in their 6-minute walk, compared
to the control group (from 355.4 to 381.9 versus from 353.1
to 345.6 m, respectively; mean difference=+34.1 m; 95%
confidence interval [CI]=+14.6, +53.5; P<0.001) (Table 2;
Figure 2). These results did not substantially change in
multiple imputation analyses. For example, in multiple impu-
tation analyses in which decedents were excluded, partici-
pants in the intervention improved from 357.5 to 383.2 m
and participants in the control group changed from 354.6 to
342.1 m (mean difference=+38.2; 95% CI=15.3 to 61.0). In
multiple imputation analyses in which decedents were
assigned a value of zero at follow-up, participants in the
intervention improved from 354.6 to 371.3 m and partici-
pants in the control group changed from 352.2 to 335.0 m
(mean difference=+33.9; 95% CI=8.5 to 59.4).
Figure 3 shows WIQ scores and accelerometer-measured
physical activity levels in the intervention and control groups at
baseline and at 6- and 12-month follow-up. Twelve-month
change from baseline in the WIQ speed score was significantly
greater in the intervention, as compared to the control group
(36.1 to 46.5 versus 34.9 to 36.5; mean difference=+8.8; 95%
CI=+1.6, +16.1; P=0.018). Twelve-month changes from base-
line in the WIQ distance score, physical activity level, and the
SF-12 PCS and MCS subscales, 6 months after the GMCB
intervention was completed, were not different between the
intervention and control groups (Table 2). For the exploratory
outcome of change in blocks walked in the past week,
participants randomized to the intervention achieved signifi-
cantly greater gains, as compared to the control group, at 12-
month follow-up, 6 months after the GMCB intervention was
completed (from 18.0 to 36.6 versus 9.3 to 12.9; mean
difference=+14.9; 95% CI=+0.2, +29.6; P=0.047). Results
were not substantially changed when analyses were repeated
using multiple imputation. However, in the multiple imputation
analyses in which decedents were assigned a zero value at
follow-up, 12-month change in the WIQ speed score was not
different between the intervention and control groups (partic-
ipants in the intervention improved from 35.1 to 44.7 m and
participants in the control group changed from 33.8 to 36.6 m
(mean difference=+6.8; 95% CI=5.1 to +14.1). When analy-
ses were repeated with adjustment for age, sex, race, and
baseline physical activity level, the result for the outcome of
12-month change in physical activity level measured by
accelerometer became nearly statistically significant (mean
12-month difference between the intervention and control
groups=+114.1 activity units; 95% CI=3.0 to +231.3;
P=0.056) and the result for patient-reported blocks walked in
the past week was no longer statistically significant (mean 12-
month difference between the intervention and control
groups=+12.6 blocks; 95% CI=2.6 to +27.8; P=0.104).
In additional exploratory analyses, there was no statisti-
cally significant interaction between intervention assignment
Control
Interven?on
Figure 2. Six-minute walk distance in the Group Oriented Arterial Leg Study (GOALS) trial at baseline,
6-month, and 12-month follow-up according to group assignment. *P values represent significant pair-wise
comparisons in change from baseline between the intervention and control groups.
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and presence versus absence of intermittent claudication in
their effect on study outcomes (data not shown).
Table 3 shows changes in study outcomes between 6- and
12-month follow-up exploratory comparisons. There were no
significant differences in change in 6-minute walk, WIQ scores,
physical activity level, or PCS or MCS scores between the
intervention and control groups during the interval between 6-
and 12-month follow-up. Within the intervention group alone,
participants experienced a statistically significant decline in 6-
minute walk between 6- and 12-month follow-up. These results
suggest that gains achieved in the 6-minute walk and the WIQ
speed score between baseline and 12-month follow-up are
primarily related to benefits attained during phase I (months 1
to 6) of the GOALS trial. When analyses in Table 3 were
repeated, adjusting for age, sex, race, and baseline acceler-
ometer-measured physical activity, the intervention group had
significantly greater decline in 6-minute walk performance
between 6- and 12-month follow-up, compared to the control
group (17.8 m; 95% CI=33.0 to 2.6; P=0.022).
Discussion
The GOALS randomized trial shows that a GMCB intervention
consisting of weekly visits to an exercise center for 6 months
in order to help PAD participants adhere to a home-based
walking exercise program has persistent efficacy at 12-month
follow-up. PAD participants randomized to the GOALS inter-
vention had significantly greater improvement in the 6-minute
walk and in the WIQ speed score at 12-month follow-up,
6 months after completing weekly on-site visits, compared to
those randomized to the control group. To our knowledge, this
is the first randomized, controlled clinical trial in people with
PAD to report 12-month changes in walking-related out-
comes, 6 months after completing an exercise intervention in
which most of the walking exercise took place at home.
These results are important because people with PAD have
significantly limited walking endurance and faster rates of
functional decline and mobility loss, compared to people
without PAD.13,15,16,27,28 Yet, few medical therapies are
available to improve walking in people with PAD. Of the 2
U.S. Food and Drug Administration (FDA)-approved medica-
tions for claudication, pentoxifylline (FDA approved in 1984) is
not substantially better than placebo,29 and cilostazol (FDA
approved in 1999) provides only modest benefit.30,31
Although supervised treadmill exercise significantly improves
walking endurance in people with PAD,1–4 supervised tread-
mill exercise is not usually paid for by medical insurance. Few
people with PAD participate in supervised exercise programs.5
Table 2. Changes Between Baseline and 12-Month Follow-up in Study Outcomes in the GOALS Trial According to Group
Assignment
Twelve-Month Change in
Outcome Measures Group N
Baseline, Mean
(SD)
Twelve-Month,
Mean (SD)
Within-Group Changes
(95% CI)
Compared to Control
(95% CI)
P Value for
Comparison
Between Baseline
and 12 Months
Six-minute walk distance, m Control 87 353.1 (92.6) 345.6 (103.3) 7.6 (21.1, +5.9) Ref 0.001
Intervention 81 355.4 (98.1) 381.9 (106.8) +26.5 (+12.5, +40.5) +34.1 (+14.6, +53.5)
Physical activity measured
over 7 days (activity units)
Control 84 673.2 (341.2) 652.0 (480.3) 21.3 (108.4, +66.1) Ref 0.455
Intervention 75 786.9 (414.0) 813.9 (355.5) +27.0 (65.5, +119.4) +48.2 (79.0, +175.4)
WIQ distance score
(0 to 100 scale, 100=best)
Control 85 32.8 (25.4) 36.3 (27.6) +3.5 (2.1, +9.2) Ref 0.139
Intervention 81 34.4 (27.2) 44.0 (30.8) +9.6 (+3.8, +15.4) +6.1 (2.0, +14.2)
WIQ speed score
(0 to 100 scale, 100=best)
Control 87 34.9 (23.1) 36.5 (24.5) +1.6 (3.5, +6.7) Ref 0.018
Intervention 81 36.1 (24.0) 46.5 (24.7) +10.5 (+5.2, 15.7) +8.8 (+1.6, +16.1)
WIQ stair climbing score
(0 to 100 scale, 100=best)
Control 87 46.8 (25.2) 50.6 (28.4) +3.8 (1.1, +8.7) Ref 0.246
Intervention 81 49.7 (26.1) 57.7 (25.5) +8.0 (+2.9, +13.0) +4.1 (2.9, +11.2)
Physical component summary
(PCS) from SF-12
Control 87 40.0 (5.1) 40.9 (5.4) +0.9 (0.5, +2.2) Ref 0.900
Intervention 81 40.6 (6.4) 41.6 (5.9) +1.0 (0.4, +2.4) +0.1 (1.8, +2.1)
Mental component summary
(MCS) from SF-12
Control 87 38.4 (5.6) 38.8 (7.3) +0.5 (1.1, +1.9) Ref 0.350
Intervention 81 39.4 (6.0) 38.8 (6.6) 0.6 (2.1, +1.0) 1.0 (3.2, +1.1)
Patient-reported blocks
walked in the past week
Control 87 9.3 (14.0) 12.9 (26.2) +3.6 (6.6, +13.9) Ref 0.047
Intervention 81 18.0 (38.2) 36.6 (58.3) +18.5 (8.0, +29.1) +14.9 (+0.2, +29.6)
GOALS indicates Group Oriented Arterial Leg Study; SF-12, the Medical Outcomes Study 12-Item Short-Form Health Survey; WIQ, Walking Impairment Questionnaire.
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Exercise programs that are less burdensome for PAD patients,
encourage home-based walking exercise, and provide contin-
ued benefit during long-term follow-up are needed to help
PAD participants avoid mobility loss and functional decline. In
the GOALS randomized trial, the first 6 months of the
intervention (phase I) required weekly visits to the medical
center and the final 6 months (phase II) consisted of
telephone contact only and did not require regular travel to
the medical center.
Three clinical trials of home-based exercise in people with
PAD completed in the late 20th and early 21st centuries were
small and inconclusive.32–34 Three recent randomized trials of
home-based exercise in PAD with follow-up ranging from 3 to
6 months reported conflicting results.6,35,36 First, Collins
et al. randomized 145 participants with PAD and diabetes to
either a home-based exercise program or a control group. The
intervention consisted of a 1-hour instruction session at
baseline and 2 exercise sessions with feedback on walking
exercise and group interaction. Participants were subse-
quently asked to attend 1 group exercise session per week
and walk for exercise at home at least 3 times weekly, using
pedometers for self-monitoring. Participants also received
biweekly telephone calls. However, at 6-month follow-up, the
intervention and control groups did not differ in change in
maximum treadmill walking distance. Second, Gardner et al.
randomized 119 participants with PAD and IC to: (1) home-
based walking exercise; (2) supervised treadmill exercise; or
(3) control.36 Participants in the home-based intervention
were asked to walk 3 times weekly for 45 minutes per
session, provided with a motion sensor to track their
progress, and met with an investigator every 2 weeks to
receive feedback. At 12-week follow-up, participants in the
home-based intervention increased their maximal treadmill
walking time by 31% and those in the supervised exercise
intervention increased their maximal treadmill walking time by
66%. Each exercise group significantly increased their tread-
mill walking time, as compared to the control group.36
However, study duration was only 12 weeks, the drop-out
Figure 3. Outcomes in the GOALS trial at baseline, 6-month, and 12-month follow-up according to group assignment. *P values represent
significant pair-wise comparisons in change from baseline between the intervention and control groups. GOALS indicates Group Oriented
Arterial Leg Study; WIQ, Walking Impairment Questionnaire.
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rate was 25%, and the investigators did not report on longer-
term follow-up data. Third, primary outcomes of the GMCB
intervention for the GOALS trial were measured at 6-month
follow-up. At 6-month follow-up of GOALS, participants in the
intervention achieved greater improvement in the 6-minute
walk test, whereas the control group declined (+42.4 versus
11.4 m; P<0.001). At 6-month follow-up of GOALS, PAD
participants also achieved significantly greater increases in
the WIQ distance score, WIQ speed score, and accelerometer-
measured physical activity, compared to the control group.6
Our results reported here show that gains in the 6-minute
walk and in the WIQ speed score are maintained at 12-month
follow-up, 6 months after weekly on-site visits in the GOALS
trial were completed.
Previous study demonstrates that benefits of supervised
exercise training are not sustained after the supervised
exercise program has been completed.33 In contrast to
supervised exercise, our GMCB intervention was designed to
help patients with PAD overcome barriers to home-based
walking exercise activity. Our GOALS intervention is similar to
a previous intervention that achieved significant gains in long-
term adherence to exercise in patients eligible for cardiac
rehabilitation.37 Our GMCB intervention incorporated self-
regulation skills and group support to help PAD patients
develop a regular habit of home-based walking exercise that
could be sustained even after the weekly on-site GMCB
intervention was completed. However, our results showed
that not all gains achieved at the end of the 6-month GMCB
intervention were sustained at 12-month follow-up. Specifi-
cally, significant improvements in physical activity level and
the WIQ distance score observed at 6-month follow-up were
not maintained at 12-month follow-up.
The reason for absence of a sustained benefit of our
intervention on accelerometer-measured physical activity
levels, despite a sustained benefit on 6-minute walk perfor-
mance, is unclear. However, it is important to point out that
the intervention had a sustained benefit on patient-reported
physical activity, measured by the number of city blocks
walked in the past week. It is possible that, over time, less
physical activity was required to achieve a continued
improvement in 6-minute walk performance. Further study
is needed to determine the dose and intensity of exercise that
achieves sustained improvement in functional performance
in PAD.
The GOALS trial has limitations. First, results may not be
generalizable to patients with PAD who did not meet our
inclusion criteria. Second, the GMCB intervention required
group support. Groups of patients with PAD can be difficult to
assemble. Third, the GOALS trial included 6 months of on-site
group meetings followed by 6 months of telephone contacts.
Table 3. Changes in Study Outcomes Between 6- and 12-Month Follow-up in the GOALS Trial According to Group Assignment
Twelve-Month Change in
Outcome Measures Group N
Six-Month
Follow-up,
Mean (SD)
Twelve-Month
Follow-up,
Mean (SD)
Six- to 12-Month
Within-Group
Changes (95% CI)
Twelve-Month Compared
to 6-Month Follow-Up
(95% CI)
P Value for
Comparison Between
6- and 12-Month
Values
Six-minute walk distance,
m
Control 87 347.7 (101.0) 345.6 (103.3) 2.2 (12.6, +8.3) Ref 0.095
Intervention 81 396.8 (103.7) 381.9 (106.8) 15.0 (25.8, 4.1) 12.8 (27.9, +2.2)
Physical activity measured
over 7 days (activity
units)
Control 84 640.6 (339.3) 652.0 (480.3) 11.4 (56.7, +79.5) Ref 0.186
Intervention 75 869.2 (407.4) 813.9 (355.5) 55.4 (127.4, +16.7) 66.8 (165.9, +32.4)
WIQ distance score (0 to
100 scale, 100=best)
Control 85 34.6 (27.3) 36.3 (27.6) +1.7 (3.4, +6.8) Ref 0.224
Intervention 81 46.8 (29.6) 44.0 (30.8) 2.8 (8.0, +2.4) 4.5 (11.8, +2.8)
WIQ speed score (0 to 100
scale, 100=best)
Control 87 36.7 (24.4) 36.5 (24.5) 0.2 (4.9, +4.5) Ref 0.780
Intervention 81 47.7 (26.0) 46.5 (24.7) 1.1 (6.0, +3.7) 1.0 (7.7, +5.8)
WIQ stair climbing score (0
to 100 scale, 100=best)
Control 87 49.7 (27.2) 50.6 (28.4) +0.9 (4.0, +5.9) Ref 0.758
Intervention 81 57.9 (24.3) 57.7 (25.5) 0.2 (5.4, +4.9) 1.1 (8.3, +6.0)
Physical component
summary (PCS) from SF-
12
Control 87 39.9 (5.5) 40.9 (5.4) +1.0 (0.3, +2.2) Ref 0.726
Intervention 81 40.9 (6.0) 41.6 (5.9) +0.7 (0.6, +2.0) 0.3 (2.1, +1.5)
Mental component
summary (MCS) from
SF-12
Control 87 38.6 (5.9) 38.8 (7.3) +0.2 (1.3, +1.7) Ref 0.367
Intervention 81 39.6 (5.8) 38.8 (6.6) 0.8 (2.4, +0.7) 1.0 (3.2, +1.2)
Blocks walked in the past
week
Control 87 14.0 (19.9) 12.9 (26.2) 1.1 (9.3, +7.1) Ref 0.752
Intervention 81 39.6 (46.5) 36.6 (58.3) 3.0 (11.5, +5.5) 1.9 (13.7, +9.9)
GOALS indicates Group Oriented Arterial Leg Study; SF-12, the Medical Outcomes Study 12-Item Short-Form Health Survey; WIQ, Walking Impairment Questionnaire.
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Our study design does not allow us to determine the degree to
which the telephone contacts were important in maintaining
home-based walking exercise behavior. Fourth, the first
6 months of the GOALS trial required weekly visits to the
medical center and consisted of a somewhat complex
intervention requiring group support and a facilitator. The
once-weekly frequency of on-site visits and the complexity of
the group intervention may not be easy to replicate in clinical
practice. Further study is needed to determine whether the
GOALS intervention is effective with fewer on-site visits. Fifth,
our study design does not allow us to discern which
components of the first 6 months of the intervention may
have been responsible for the continued improvement
observed at 12-month follow-up. Sixth, patient-reported
blocks walked during the past week as a measure of physical
activity at 12-month follow-up has limitations.
In summary, a 6-month walking exercise intervention that
employed GMCB methods and encouraged regular home-
based exercise continued to benefit PAD participants at 12-
month follow-up. Further study is needed to determine
whether continued benefits are observed beyond 12 months
and to determine whether a more intensive intervention after
the 6-month on-site GMCB intervention would achieve even
greater improvement at 12-month follow-up.
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